Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide

What Was Tested

This randomized controlled trial paper looks at Liraglutide.

Who Took Part

The study group was 564 adults.

The age groups tagged for this paper are teenagers, young adults, adults, middle-aged adults and older adults, both men and women.

A total of 564 adults (n=90-98 per group; body mass index 30-40 kg m(-2)) enrolled, 398 entered the extension and 268 completed the 2-year trial.

How the Study Was Run

The researchers set it up as a randomized, double-blind, open-label and placebo-controlled study.

Because people in this Liraglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the adults nor the staff measuring them knew who was on Liraglutide, so expectations could not easily colour the readings.

Being open-label, the Liraglutide study did not mask who received what.

The comparison arm used a placebo, so changes seen with Liraglutide could be set against what happens without it.

The trial ran from January 2007-April 2009 and is registered with Clinicaltrials.gov, number NCT00480909.

What Was Measured

PubMed files the paper under topics including Analysis of Variance, Anti-Obesity Agents, Europe, Exercise Therapy, Glucagon-Like Peptide 1, Liraglutide and Obesity.

What This Means in Plain Language

The paper is a randomized, double-blind and open-label study of Liraglutide in 564 adults.

With several hundred people or more, it is a fairly large study for this kind of research.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2012 (International journal of obesity (2005)), a journal based in England.

More context: the Liraglutide compound page.